Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) is anticipated to release its earnings data before the market opens on Monday, March 17th. Analysts expect Abeona Therapeutics to post earnings of ($0.35) per share and revenue of $0.10 million for the quarter.
Abeona Therapeutics Trading Up 0.2 %
NASDAQ ABEO opened at $5.29 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The stock’s 50-day moving average is $5.51 and its 200-day moving average is $5.84. The firm has a market cap of $229.96 million, a P/E ratio of -1.97 and a beta of 1.79. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.87.
Wall Street Analysts Forecast Growth
ABEO has been the subject of several research analyst reports. Oppenheimer initiated coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They set an “outperform” rating and a $16.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, February 19th. Finally, StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Abeona Therapeutics has an average rating of “Moderate Buy” and an average target price of $17.50.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also
- Five stocks we like better than Abeona Therapeutics
- Basic Materials Stocks Investing
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- The How And Why of Investing in Oil Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Stock Sentiment Analysis: How it Works
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
